Linerixibat is the generic name for a medication that is marketed under the brand name Livmarli [1][2].
What is Livmarli used for?
Livmarli is a medication prescribed for the treatment of cholestatic pruritus in adult and pediatric patients one year of age and older with Alagille syndrome [2][3]. Alagille syndrome is a genetic disorder that can affect the liver, heart, eyes, and other parts of the body [3]. Cholestatic pruritus refers to itching caused by impaired bile flow [4].
How does Livmarli work?
Linerixibat, the active ingredient in Livmarli, is an ileal bile acid transporter (IBAT) inhibitor [1][5]. IBAT is responsible for reabsorbing bile acids in the intestine [5]. By inhibiting IBAT, linerixibat reduces the reabsorption of bile acids, leading to increased excretion of bile acids in the stool and a decrease in bile acid levels in the liver [5]. This mechanism helps to alleviate the cholestatic pruritus associated with Alagille syndrome [4][5].
Who manufactures Livmarli?
Livmarli is manufactured by Mirum Pharmaceuticals [2].
What are the potential side effects of Livmarli?
Common side effects of Livmarli include diarrhea, vomiting, abdominal pain, and nausea [2]. Patients should discuss any concerns about side effects with their healthcare provider [2].
How is Livmarli administered?
Livmarli is an oral medication [2]. Dosing varies depending on the patient's age and weight [2].
Are there any clinical trials for Linerixibat?
Clinical trials have investigated the efficacy and safety of linerixibat in patients with Alagille syndrome and other cholestatic liver diseases. Studies have shown that linerixibat can reduce serum bile acid levels and improve pruritus [5].